Skip to main content

Table 1 the comparison of clinical characteristics between patients with or without CNS involvement

From: BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase

Characteristics

With CNS involvement

Without CNS involvement

P value

 

N=14

N=26

 

Age, median (range, year)

44.0 (23.0-62.0)

51.0(15-75)

.392

Gender, men, n(%)

9 (34.6%)

10(71.4%)

.046

B symptoms, n (%)

10 (71.4%)

15(57.7%)

.502

Elevated LDH, n (%)

14 (100%)

16(61.5%)

.007

Median WBC×109/l (range)

17.2 (1.2-66.57)

9.58(1.38-40.06)

.729

Median Hb, g/l (range)

95.0 (61.0-145.0)

100.5(45.0-141.0)

.777

Median PLT, ×109/l (range)

73.5 (20.0-355.0)

113.0(3.0-509.0)

.843

International Prognostic

  

.002

Index, n (%)

0

9 (34.6%)

 

2

6 (42.9%)

14(53.8%)

 

3

8 (57.1%)

3(11.5%)

 

4-5

  

.896

Treatment, n (%)

4 (28.6%)

10(38.5%)

 

CHOP/CHOP-like

1 (7.1%)

3(11.5%)

 

R- CHOP/CHOP-like

4 (28.6%)

5(19.2%)

 

Intensive regimes

5 (35.7%)

8(30.8%)